[Use of methotrexate in spondylarthropathies. Review of the literature]

Rev Med Interne. 1996;17(4):333-9. doi: 10.1016/0248-8663(96)81439-1.
[Article in French]

Abstract

Methotrexate (MTX) is one of the most effective treatments of rheumatoid arthritis. It has also been used in other conditions such as spondylarthropathies (SPA). The literature concerning MTX in SPA was reviewed. Thus, MTX has been mainly prescribed in psoriatic arthritis and Reiter's syndrome with success for dermatological manifestations of these diseases. However, only a few controlled trials have been conducted in psoriatic arthritis and only one placebo controlled study did not demonstrate a real beneficial effect. Furthermore, it seems that MTX has no influence on the radiological outcome of psoriatic arthritis. There has been no controlled study upon the efficacy of MTX in Reiter's syndrome, ankylosing spondylitis or arthropathy associated with inflammatory bowel diseases. Such studies in SPA are required to evaluate the responding conditions, the efficacy, the side-effects, and the effective dose of MTX.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antimetabolites / therapeutic use*
  • Folic Acid Antagonists / therapeutic use*
  • Humans
  • Joint Diseases / drug therapy*
  • Methotrexate / therapeutic use*
  • Spondylitis / drug therapy*
  • Spondylitis, Ankylosing / drug therapy*

Substances

  • Antimetabolites
  • Folic Acid Antagonists
  • Methotrexate